140 related articles for article (PubMed ID: 37832108)
1. Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience.
Pehlivan M; Paksoy N; Aydin E; Basaran M; Ekenel M
Medicine (Baltimore); 2023 Oct; 102(41):e35245. PubMed ID: 37832108
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
4. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
[TBL] [Abstract][Full Text] [Related]
5. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
Halit Aktepe O; Sinem Ardic F; Yuce D; Can Guven D; Guner G; Cagri Yildirim H; Kilickap S; Turker A; Kertmen N; Akin S; Aksoy S; Dizdar O; Yalcin S; Erman M
J BUON; 2021; 26(5):2067-2073. PubMed ID: 34761618
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
[TBL] [Abstract][Full Text] [Related]
9. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
10. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
13. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
[TBL] [Abstract][Full Text] [Related]
14. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.
Bamias A; Zakopoulou R; Tzannis K; Sakellakis M; Koutsoukos K; Kyriazoglou A; Panagiotou A; Armylagos S; Rokas K; Gotzias D; Boulouta A; Bozionelou V; Stravodimos K; Varkarakis I; Mavroudis D; Dimopoulos MA
Anticancer Drugs; 2023 Mar; 34(3):413-421. PubMed ID: 36730619
[TBL] [Abstract][Full Text] [Related]
15. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
Numakura K; Kobayashi M; Muto Y; Sekine Y; Takahashi M; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Nanjyo H; Habuchi T
Sci Rep; 2020 Nov; 10(1):20089. PubMed ID: 33208816
[TBL] [Abstract][Full Text] [Related]
16. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
Tamura K; Osawa T; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Sugimoto M; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Komiyama M; Tanaka K; Yokomizo A; Kohei N; Shinohara N; Miyake H;
Jpn J Clin Oncol; 2021 Apr; 51(5):810-818. PubMed ID: 33479762
[TBL] [Abstract][Full Text] [Related]
17. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
18. A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan.
Kato T; Yumiba S; Nakata W; Nakano K; Nagahara A; Matsuzaki K; Hayashi Y; Hatano K; Kawashima A; Takao T; Nishimura K; Nakai Y; Nakayama M; Nishimura K; Takada S; Tsujihata M; Uemura M; Nonomura N; Imamura R
Int J Urol; 2023 Sep; 30(9):723-729. PubMed ID: 36578154
[TBL] [Abstract][Full Text] [Related]
19. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
